

—Inflation Reduction Act Research Series—

NovoLog/Fiasp: Medicare Enrollee Use and Spending

This Fact Sheet provides information on **NovoLog/Fiasp**,* one of the 10 drugs selected for the first cycle of Medicare drug price negotiations. NovoLog/Fiasp (active ingredient insulin aspart, human) is a biological product used to treat diabetes. About 28 percent of Medicare enrollees have diabetes, which also increases their risk for heart disease and stroke.

- Between 2018 and 2022, average annual total Part D spending per enrollee taking NovoLog/Fiasp (i.e., the total amount, including Medicare, plan, and enrollee payments, spent on NovoLog/Fiasp per person) increased by 11 percent (from \$3,002 to \$3,323).
- From 2018 through 2022, the average annual out-of-pocket spending per enrollee decreased by 28 percent (from \$168 to \$121).

Table 1 presents data on utilization and spending for NovoLog/Fiasp among Part D enrollees. About 763,000 Part D enrollees filled prescriptions for NovoLog/Fiasp in 2022. Relative to the total Part D population, a greater share of NovoLog/Fiasp users were under the age of 65 (30 percent vs. 19 percent) and Black non-Latinos (17 percent vs. 11 percent).

Table 1. Medicare Part D Use and Spending on NovoLog/Fiasp, Calendar Year (CY) 2022

	Total Enrollees	LIS Enrollees ^a	Non-LIS Enrollees
Number of Part D Enrollees	53,063,000	14,957,000	38,106,000
Number of Enrollees Taking NovoLog/Fiasp	763,000	431,000	332,000
Share of Part D Enrollees Taking NovoLog/Fiasp	1%	3%	1%
Total Spending on NovoLog/Fiasp			
Total Spending	\$2,535,770,000	\$1,400,059,000	\$1,135,711,000
Average per Enrollee taking NovoLog/Fiasp	\$3,323	\$3,248	\$3,421
Enrollee Out-of-Pocket Spending on NovoLog/Fiasp			
Total OOP Spending	\$92,672,000	\$6,140,000	\$86,532,000
Average OOP per Enrollee taking NovoLog/Fiasp	\$121	\$14	\$261

Notes: ^aFor eligible Part D enrollees who meet income and asset requirements, the Low-Income Subsidy (LIS), also known as Extra Help, provides assistance with premiums, deductibles, and co-payments for covered Part D drugs.

The Inflation Reduction Act was signed into law by President Biden in August 2022. Please see [here](#) for more information on how the law is reducing drug costs for Medicare beneficiaries.

Please see [here](#) for more information on NovoLog/Fiasp and the other drugs selected for the first cycle of Medicare drug price negotiation, cautions and limitations in interpretation and use of these estimates, and relevant citations.

* The drug is also identified with the proprietary names: NovoLog, NovoLog FlexPen, NovoLog PenFill, Fiasp, Fiasp FlexTouch, and Fiasp PenFill.